bpc-157 safety adverse events case report human effects Potential Side Effects of BPC-157 for Men Preventable Adverse Event Reporting |

CJC-1295 DAC (5 mg Vial): Advanced / Aggressive Approach (1 mL = 5 mg/mL) Reconstitute: Add 1.0 mL bacteriostatic water to one 5 mg vial higher concentration 5 mg/mL

No human study has tracked cancer incidence following BPC-157 administration, leaving the oncological risk profile unresolved and requiring cautious evaluation before use in individuals with active or prior malignancies

Besides, BPC 157 promptly ameliorates both skin and stomach mucosa healing and induces closure of fistulas, with no leakage after up to 20 ml water intragastrically, including also counteraction of 6-alpha-methylprednisolone aggravation (Skorjanec et al., 2009)

Competitive or tested athletes BPC-157 has been on the World Anti-Doping Agency Prohibited List under category S0 since 2022 and remains on the 2025 list